*Disclaimer

MGC PHARMACEUTICALS LTD (ASX: MXC)

🔗 📄 📈

MXC: Malta Production Facility Receives EU-GMP Approval

MGC PHARMACEUTICALS LTD

2023-05-02 09:03:00

MXC: Fundraise closed raising up to a total of GBP 2.09m

MGC PHARMACEUTICALS LTD

2023-04-13 10:00:00

MXC: CannEpil now available by Named Patient Request in UK

MGC PHARMACEUTICALS LTD

2023-04-11 17:12:00

MXC: MGC Receive Permission for Psilocybin Research & Development

MGC PHARMACEUTICALS LTD

2023-04-03 08:38:00

MXC: ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order

MGC PHARMACEUTICALS LTD

2023-03-21 09:19:00

MXC: Completion of CimetrA Mechanism of Action study

MGC PHARMACEUTICALS LTD

2023-03-07 09:52:00

MXC: Provision of US$600,000 Funding and change of CFO

MGC PHARMACEUTICALS LTD

2023-02-03 14:43:00

MXC: Refinancing and Extension to Convertible Security Agreements

MGC PHARMACEUTICALS LTD

2023-02-02 12:36:00

MXC: Results of CimetrA bioanalytics pre-clinal trial

MGC PHARMACEUTICALS LTD

  1. MGC Pharma has completed the full pre-clinical rodents study panel for Cimetr ATM.
  2. The study results are an important step ahead of the submission to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) approval.
  3. No anomalies were observed in the biopsies, nor were any clinical or behavioural adverse events recorded.

2023-01-10 08:50:00

MXC: Internal Costs Review Completed and Board Change

MGC PHARMACEUTICALS LTD

  1. The board has implemented further cost reductions to enable the company to direct more of its working capital to clinical trial and research programs in 2023.
  2. Board have agreed to an immediate ~35% reduction in director fees, effective from 1 December 2022.
  3. Key executive officer team have agreed to a 10-20% reduction in their cash remuneration, with only key executive officers to be issued MGC shares in lieu of the reduction.

2023-01-03 08:23:00